Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Consensus Price Target of $20.98 According to Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus recommendation of “Hold” from the twenty-three brokerages that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $20.98.

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Canaccord Genuity Group restated a “buy” rating and set a $49.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. Finally, New Street Research set a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th.

Insider Buying and Selling

In related news, EVP J III sold 4,677 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Michael Dube sold 2,641 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by company insiders.

Institutional Trading of Intellia Therapeutics

Institutional investors have recently modified their holdings of the company. Opaleye Management Inc. lifted its holdings in shares of Intellia Therapeutics by 2.0% in the second quarter. Opaleye Management Inc. now owns 250,000 shares of the company’s stock valued at $4,230,000 after buying an additional 5,000 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Intellia Therapeutics during the second quarter worth about $34,000. Arizona State Retirement System raised its position in Intellia Therapeutics by 17.0% in the second quarter. Arizona State Retirement System now owns 35,356 shares of the company’s stock worth $598,000 after acquiring an additional 5,131 shares in the last quarter. Nykredit A S bought a new stake in Intellia Therapeutics in the second quarter worth about $33,000. Finally, Wellington Grp LLC lifted its holdings in Intellia Therapeutics by 46.2% in the 2nd quarter. Wellington Grp LLC now owns 67,688 shares of the company’s stock valued at $1,145,000 after acquiring an additional 21,391 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $12.16 on Tuesday. The business’s fifty day moving average price is $11.96 and its two-hundred day moving average price is $13.29. The company has a market capitalization of $1.70 billion, a P/E ratio of -3.62 and a beta of 1.82. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.80). The company had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The firm’s quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.98) EPS. On average, research analysts expect that Intellia Therapeutics will post -3.21 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing curative treatments using CRISPR-based gene-editing technology. The company’s approach is designed to make targeted changes to disease-associated genes, including through in vivo therapies that edit genes directly inside the body.

Intellia’s pipeline includes NTLA-2001, an investigational treatment designed to address transthyretin amyloidosis by editing the TTR gene, and NTLA-2002, an investigational therapy targeting hereditary angioedema through editing of the KLKB1 gene.